#bispecific antibodies

All articles tagged with "bispecific antibodies"

Nature Medicine published a randomized phase 2 trial on 11 September 2026 comparing teclistamab with lenalidomide-dexamethasone in high-risk smoldering multiple myeloma.
The study is known as ImmunoPRISM and focuses on the precursor stage of multiple myeloma.
Teclistamab is a BCMA-directed bispecific antibody; lenalidomide plus dexamethasone is an established all-oral combination.
The journal summary reports a higher result for patients on the trial's highlighted measure, with full data in the paper.

DT Editorial Team·Sep 12, 2026·via nature.com

A phase 1 trial tested cevostamab in 324 patients with relapsed or refractory multiple myeloma.
Most participants had heavily pretreated disease, and nearly half had prior BCMA-targeted therapy.
The drug produced a 42.1% objective response rate and a median response duration of 11.2 months.
The maximum tolerated dose was not reached, though serious adverse events were common.

DT Editorial Team·Jul 25, 2026·via nature.com

Wistar researchers reported a preclinical ovarian cancer immunotherapy study in Molecular Therapy.
The platform uses DNA delivery so the body can produce bispecific T cell engagers rather than relying only on conventional protein manufacturing.
The approach also supports dual antigen targeting in a single dose, aimed at reducing tumor escape and resistance.

DT Editorial Team·Jul 19, 2026·via medicalxpress.com